Audion Announces Investment and Licensing Deal with Lilly
News Feb 11, 2014
Audion Therapeutics has announced that it has received a Series A investment from Eli Lilly and Company to enable the company to progress its programs targeting sensorineural hearing loss.
As part of the investment, the parties also entered into a licensing agreement that gives Audion the rights to certain Lilly compounds that can be developed to potentially treat hearing loss by hair cell regeneration.
Under the terms of the license, Lilly has an option to reacquire these rights upon successful clinical Proof of Concept. Financial terms were not disclosed. Following the investment, Mr. Shaun Hawkins, Vice President of Lilly New Ventures, has become a member of Audion’s Supervisory Board.
Rolf Jan Rutten, CEO of Audion commented: “This commitment by Lilly is an important next step in the development of our company. The investment validates our scientific approach and it underlines the potential of our hair cell regeneration program. It allows us to expand our infrastructure with a laboratory facility in Cambridge, Mass. and gives us access to a selection of Lilly’s potent, proprietary molecules that will push Audion’s lead program significantly forward”.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019